The serotonergic hypothesis, proposed by Mayeux and colleagues, interprets the overall reduction of serotonin in PD as a physiological compensatory mechanism for the reduced availability of striatal dopamine increasing risk factor for depression 31,32 33. The dopaminergic hypothesis of Fibiger is based on the fact that not only the nigrostriatal, but also the mesocortical and mesolimbic dopaminergic projections degenerate in PD. As these projections play an important role in selfreward mechanisms, it is hypothesized that damage to these reward-related systems may be a risk factor for depression34 (LEENTJENS ET AL). These findings support the view that depression can be early premotor manifestation of PD. Why predict PD? depression is a common and potentially debilitating aspect of Parkinson’s disease, (Postuma et al.), it has an adverse effect on the quality of patients’ lives. So, the most elusive goal in neurodegeneration is a neuroprotective agent, that could positively impact on quality of life and clinical outcomes in patients with
The serotonergic hypothesis, proposed by Mayeux and colleagues, interprets the overall reduction of serotonin in PD as a physiological compensatory mechanism for the reduced availability of striatal dopamine increasing risk factor for depression 31,32 33. The dopaminergic hypothesis of Fibiger is based on the fact that not only the nigrostriatal, but also the mesocortical and mesolimbic dopaminergic projections degenerate in PD. As these projections play an important role in selfreward mechanisms, it is hypothesized that damage to these reward-related systems may be a risk factor for depression34 (LEENTJENS ET AL). These findings support the view that depression can be early premotor manifestation of PD. Why predict PD? depression is a common and potentially debilitating aspect of Parkinson’s disease, (Postuma et al.), it has an adverse effect on the quality of patients’ lives. So, the most elusive goal in neurodegeneration is a neuroprotective agent, that could positively impact on quality of life and clinical outcomes in patients with